Other immune-checkpoint inhibitors launched with FDA approval to improve the prognosis of patients not responding to traditional ICIs include treatments targeting the lymphocyte-activation gene-3 (LAG-3), which is involved in the interaction between lymphocytes and cancer cells, dendritic cells, and myeloid-derived suppressor cells, leading to the suppression of T-cell function and the inhibition of cytokine secretion [119]. This evidence concerns the gene LAG3 and cancer.